Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPAR-γ) gene and risk of prostate cancer among men in a large cancer prevention study

The nuclear hormone receptor peroxisome proliferator-activated receptor-gamma (PPAR-γ) may play a role in prostate carcinogenesis. We examined the association between the PPAR-γ Pro12Ala polymorphism and prostate cancer risk in a cohort of Finnish male smokers. In a nested case-control analysis that included 193 prostate cancer cases and 188 matched controls, we found no significant association between this polymorphism and prostate cancer risk (odds ratio, OR=1.27, 95% confidence interval, CI: 0.83–1.94), or significant trend or association with tumor stage (OR=1.28, 95% CI: 0.54–3.04 for metastatic disease) or grade (OR=1.57, 95% CI: 0.63–3.91 for poorly differentiated disease). The Pro12Ala polymorphism does not appear to play a significant role in prostate cancer risk in this cohort of men.